Seminars article
Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers

https://doi.org/10.1016/j.urolonc.2017.09.023Get rights and content

Abstract

The recent resurgence of immunotherapy has transformed the therapeutic field of advanced urologic cancers. In this seminars issue, we evaluate the role of emerging and recently approved immunotherapeutic agents in advanced prostate, urothelial, and renal cell carcinoma. In each of these fields, we discuss recent regulatory approvals as well as promising ongoing clinical trials. Finally, we discuss incidence and management of immune related adverse events specifically associated with PD-1/PD-L1 inhibitors.

Cited by (11)

  • Combined chemotherapy and radiotherapy improves survival in 1897 testicular Lymphoma patients from a contemporary cohort

    2020, Urologic Oncology: Seminars and Original Investigations
    Citation Excerpt :

    The NCDB, a clinical oncology database jointly sponsored by the American College of Surgeons and the American Cancer Society, was used for these analyses. NCDB is sourced from hospital registry data collected from more than 1,500 Commission-on-Cancer accredited facilities and includes data on over 70% of all malignancies diagnosed in the United States [10]. Our Institutional Review Board waived approval for this study because NCDB patient and facility data is deidentified.

  • Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review

    2019, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    Over the last decade, in the so-called “antiangiogenic era”, a number of targeted therapies have been approved for the treatment of metastatic renal cell carcinoma (mRCC) (Choueiri and Motzer, 2017; Vitale and Carteni, 2016). More recently, immunotherapy has undergone a resurgence in clinical practice (Gill and Agarwal, 2017). In 2016 the European Society for Medical Oncology (ESMO) guideline still recommended bevacizumab plus interferon (IFN)-α, sunitinib or pazopanib as first-line treatment in patients with good or intermediate risk and clear-cell histology and temsirolimus for the poor risk cases (Escudier et al., 2016).

View all citing articles on Scopus
View full text